Prescription Medicines
Ketolan Inj.
- Product Category
- Safe and powerful non-narcotic pain reliever
- Active Ingredients
- Ketorolactromethamine
- Appearance
- Brown ampoule injection with pale yellow transparent liquid
- Reimbursement Code
- 648102001
01 / 02
1. Composition and Strength
- Active ingredient: Ketorolactromethamine (USP)----30mg
- Additives: Sodium hydroxide, ethanol, sodium chloride, water for injection
2. Effectiveness
1. Short-term therapy for moderate and severe acute pain (including postoperative pain)
2. Children over 2 years of age
Severe postoperative pain for which narcotic analgesics are contraindicated
3. Dosage and dosage
○ Adults: As a ketorolactromethamine salt, 10 mg is administered as an initial dose when administered intramuscularly or intravenously, and a maintenance dose of 10 to 30 mg is administered every 4 to 6 hours. Administer the lowest effective dose. The administration period does not exceed 2 days.
The daily dose should not exceed 90 mg (60 mg for the elderly, patients with renal impairment, and patients weighing less than 50 kg).
Epidural and spinal administration is not performed. The dosage or administration interval can be adjusted depending on the severity of symptoms and pain. Morphine can be administered concurrently if necessary.
○ Children over 2 years of age: Administer as a single intravenous injection after pediatric surgery. Afterwards, it can be administered as an intravenous bolus several times as needed. Since intramuscular injection is painful, intravenous injection is recommended for children. After a single dose of 0.5 to 1.0 mg per kg of body weight, administer 0.5 mg per kg of body weight every 6 hours if necessary. The administration period should not exceed 2 days.
The dosage or administration interval can be adjusted depending on the severity of symptoms and pain.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) The most serious adverse reactions include the following, and caution must be exercised as they may lead to fatal results.
(1) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Clinical trials and epidemiological data suggest that the use of COX-2 inhibitors and some NSAIDs, especially at high doses, may slightly increase the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Although ketorolac has not been shown to increase thrombotic adverse events, such as myocardial infarction, there are insufficient data to rule out this risk. This drug should be administered with careful consideration to patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease. Additionally, similar precautions should be taken before starting treatment with this drug in patients with risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, smoking).
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
(2) Hematological risk: Caution should be exercised when administering to patients with coagulation disorders, and patients should be carefully monitored. Although significant interactions between this drug and warfarin or heparin have not been identified in several studies, the risk of bleeding may be increased during concurrent administration of this drug with drugs that affect hemostasis (therapeutic doses of warfarin, heparin, and dextran). In post-marketing studies, signs of postoperative hematoma and wound bleeding have been reported in patients who received intravenous administration of this drug during surgery. The specialist should be aware of the risk of bleeding during surgeries where hemostasis is important, such as (but not limited to) prostatectomy, tonsillectomy, or plastic surgery.
(3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Elderly and debilitated patients may be at greater risk for serious gastrointestinal adverse events.
The possibility of serious gastrointestinal side effects may increase as the administration period and dosage increase, but this risk cannot be completely excluded during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
(4) Kidney: Adverse reactions to the kidneys, ranging from interstitial nephritis to acute renal failure, may occur, and patients with renal disease should be especially careful. When injected, the daily dose should not exceed 60 mg.
(5) Hypersensitivity reaction: Hypersensitivity symptoms such as anaphylaxis, bronchospasm, vascular collapse, hives, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), and vesicular rash may occur. Particular caution should be exercised in patients who have shown hypersensitivity to aspirin or other non-steroidal anti-inflammatory drugs, but the above symptoms may also occur in patients who have not shown hypersensitivity to these drugs or in patients who have not been exposed to these drugs.
(6) Pregnancy: Like other drugs known to inhibit cyclooxygenase/prostaglandin synthesis, this drug may impair fertility and is therefore not recommended for women wishing to become pregnant. Women who are having difficulty conceiving or are undergoing infertility testing should consider discontinuing treatment with this drug.
3) Do not use in combination with other non-steroidal anti-inflammatory drugs (including selective COX-2 inhibitors) as the risk of adverse reactions may increase.
4) Ampoule injections may contain glass fragments when cutting the container, which may cause adverse reactions. When using, cut carefully to minimize glass fragments, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients (cases).
1) Patients with a history of peptic ulcer or gastrointestinal ulcer/perforation
2) Patients with gastrointestinal bleeding or its history
3) Patients with a predisposition or history of bleeding
4) Patients with or suspected to have cerebrovascular hemorrhage or patients with a history of cerebrovascular hemorrhage
5) Patients who have undergone surgery and have a high risk of bleeding or incomplete hemostasis
6) Patients with moderate or severe renal failure (serum creatinine >160 μmo/L) or patients at risk of renal failure due to volume loss or dehydration
7) Patients with bronchial asthma or a history of it
8) Patients with nasal polyps, angioedema, or bronchospasm symptoms
9) Patients with hypersensitivity to this drug, its components, aspirin, or non-steroidal anti-inflammatory drugs
10) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
11) Patients who underwent tonsillectomy surgery
12) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
13) Patients receiving other non-steroidal anti-inflammatory drugs
14) Patients receiving anticoagulants, pentoxifylline, probenecid, and lithium
15) Pregnant women, women who may be pregnant, or lactating women
16) Patients with severe heart failure
17) Patients with severe liver impairment
18) Patients with hypovolemia due to dehydration or other causes
19) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
20) Infants under 2 years of age
3. Administer with caution to the following patients.
1) Patients with hepatic impairment or its history
2) Patients with renal impairment or its history
3) Elderly people
4) Patients with high blood pressure
5) Patients with fluid retention or heart failure
6) Patients with hypovolemia, dehydration, and patients taking diuretics or ACE inhibitors
7) Patients with a history of gastrointestinal diseases such as Crohn's disease or ulcerative colitis (symptoms may worsen)
8) Patients with bronchial asthma
9) Patients who have had digestive ulcers due to long-term administration of non-steroidal anti-inflammatory drugs in the past, and who require long-term administration of this drug and are concurrently being treated with peptic ulcers such as misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
4. Adverse reactions
1) Digestive system: Nausea, indigestion, gastrointestinal pain, diarrhea, sometimes constipation, abdominal distension, vomiting, stomatitis, rarely peptic ulcer, gastrointestinal bleeding, perforation, bloody stool, rectal bleeding, gastritis, burping, anorexia, increased appetite, pancreatitis, hematemesis, esophagitis, melena, dry mouth, colitis, and exacerbation of Crohn's disease.
2) Whole body: Occasionally, edema, rarely anaphylaxis, bronchospasm, laryngeal edema, tongue edema, hypotension, flushing, hypersensitivity reactions such as rash, weight gain, fever, infection, and asthenia may occur.
3) Cardiovascular system: High blood pressure, rarely flushing, palpitations, pallor, low blood pressure, syncope, bradycardia, chest pain, and heart failure may occur.
4) Skin: Redness, sometimes itching, rarely toxic epidermal necrolysis (Riel syndrome), drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), exfoliative dermatitis, papular redness, urticaria, angioedema, and sweating may occur.
5) Blood and lymphatic system: Purpura, rarely surgical site bleeding, thrombocytopenia, nosebleeds, anemia, leukopenia, eosinophilia, and hematoma may occur.
6) Nervous system: Headache, sweating, occasional drowsiness, dizziness, rarely convulsions, tremors, hallucinations, abnormal dreams, strange situation hallucinations, extrapyramidal syndrome, paresthesia, depression, insomnia, nervousness, dry mouth, severe thirst, abnormal thinking, difficulty concentrating, hyperkinesia, stupor, muscle pain, aseptic meningitis (especially those suffering from autoimmune diseases such as systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) patient), anxiety, and psychotic reactions may occur.
7) Liver: In rare cases, hepatitis, liver failure, cholestatic jaundice, and abnormal liver function test values may occur. If these symptoms appear, administration should be discontinued immediately.
8) Respiratory system: In rare cases, shortness of breath, asthma, pulmonary edema, rhinitis, and cough may occur.
9) Urinary system: In rare cases, acute renal failure, flank pain (sometimes accompanied by hematuria and azotemia), oliguria, nephritis, polyuria, frequent urination, urinary retention, hemolytic uremia, hyperkalemia, hyponatremia, nephrotic syndrome, and increased serum urea and creatinine levels may occur.
10) Others: Occasionally, pain at the injection site, abnormal taste, visual abnormality, blurred vision, optic neuritis, tinnitus, hearing loss, infertility in women, and prolonged bleeding time may occur.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient. In particular, the lowest effective dose should be used in patients weighing less than 50 kg, over 65 years of age, or with renal dysfunction, and do not exceed 60 mg per day when injected.
2) Gastrointestinal adverse reactions: In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding occurs more than 10 times when administered non-steroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding or ulcers include oral corticosteroids, anticoagulants such as warfarin, concomitant use of antiplatelet drugs such as selective serotonin reuptake inhibitors or aspirin, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Caution should be exercised when administering nonsteroidal anti-inflammatory drugs to patients with a history of inflammatory bowel disease (ulcerative enteritis, Crohn's disease) because the disease may worsen. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients. If gastrointestinal bleeding or ulceration occurs in a patient receiving this drug, administration should be discontinued.
3) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention, hypertension, and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention, heart failure, hypertension, or similar diseases.
5) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, hypovolemia, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory drugs, including this drug, may increase liver function values (AST, ALT). These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the administration period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration should be immediately discontinued.
8) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
9) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
11) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
12) Drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome): Drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome) has been reported in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these cases were fatal or life-threatening. DRESS syndrome is usually, but not always, accompanied by fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, and myositis. Sometimes the symptoms of DRESS syndrome may resemble an acute viral infection. Eosinophilia is often present.
Because this disorder is variable in its presentation, other organ systems not mentioned here may be involved. It is important to note that early symptoms of hypersensitivity, such as fever or lymphadenopathy, may appear even if the rash is not evident. If these signs or symptoms occur, this drug should be discontinued immediately and the patient evaluated.
13) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients.
14) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
15) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
16) This drug has no sedative or anti-anxiety effect and has an inhibitory effect on platelet aggregation, which delays hemostasis time and increases the risk of bleeding. Therefore, it should not be used as an anesthetic aid before surgery or during surgery.
17) This drug has not been sufficiently studied as an analgesic in the obstetric field, and it is not used in this field because it is a prostaglandin biosynthesis inhibitor and affects uterine contractions and fetal circulation.
18) Use of this drug may cause depression, insomnia, dizziness, and drowsiness. Therefore, you must be careful when driving or operating machinery.
19) Temporary infertility has been reported in women taking NSAIDs for a long time.
20) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
6. Interaction
1) ACE inhibitor or angiotensin II receptor antagonist
(1) Concurrent use with ACE inhibitors may increase the risk of kidney damage (especially in patients with volume depletion).
(2) There are reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when coadministering this drug with ACE inhibitors or angiotensin II receptor antagonists.
2) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
3) At the therapeutic concentration of salicylic acid (300 g/mL), the plasma protein content of this drug drops from 99.2% to 97.5%.
4) Diuretics (furosemide, etc.): Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
5) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
6) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered concurrently with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
7) Anticoagulants (heparin, warfarin, or coumarin)
(1) When heparin or coumarin derivatives are used together at therapeutic doses, the risk of complications due to bleeding may increase. There are no sufficient research results on the combined use of low-dose heparin (2,500-5,000 U, q12h), warfarin, and dextran, but the risk of bleeding is expected to increase.
(2) For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
(3) This drug slightly reduces the plasma protein binding rate of warfarin, but does not affect the plasma protein binding rate of this drug at the therapeutic concentration of warfarin.
8) It has been shown to reduce the requirement for opiate analgesics when administered to relieve postoperative pain.
9) The therapeutic concentrations of digoxin, ibuprofen, naproxen, acetaminophen, phenytoin, tolbutamide, and piroxicam do not affect the plasma protein rate of this drug.
10) Antihypertensive agent: Reduces antihypertensive effect.
11) Cyclosporine and tacrolimus: Nephrotoxicity may increase with concurrent administration with non-steroidal anti-inflammatory drugs.
12) Mifepristone: Non-steroidal anti-inflammatory drugs should not be administered for 8 to 12 days after taking mifepristone because they reduce the effectiveness of mifepristone.
13) Oxpentiphylline: Concomitant use should be avoided because bleeding tendency increases when administered together.
14) Quinolone antibiotics: Be careful because there is animal testing data that shows that the risk of convulsions may increase when administered in combination with non-steroidal anti-inflammatory analgesics.
15) Zidovudine: Hematological toxicity may increase when administered in combination with non-steroidal anti-inflammatory drugs. There is evidence that coadministration of zidovudine and ibuprofen in patients with HIV(+) hemophilia increases the risk of hemarthrosis and hematoma.
16) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
17) Cardiac glycosides: Non-steroidal anti-inflammatory drugs can worsen heart failure by decreasing the glomerular filtration rate and increasing the blood concentration of glycosides.
18) Corticosteroid preparations: Be careful as the risk of gastrointestinal ulcers or bleeding may increase.
7. Administration to pregnant and lactating women
1) Safety for pregnant women has not been established, so do not administer to pregnant women or women who may be pregnant.
2) Like other non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered at the end of pregnancy.
3) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased fetal survival rate.
4) It has been reported that this drug and its metabolites pass into the breast milk of fetuses and animals. Because this drug has been detected in low concentrations in human breast milk, it is not administered to nursing mothers.
8. Administration to children
Safety and efficacy in infants under 2 years of age have not been established, so do not administer to infants under 2 years of age.
9. Administration to elderly people
Elderly people are more sensitive to adverse reactions to the kidneys from non-steroidal anti-inflammatory drugs, and the incidence of adverse reactions such as gastrointestinal bleeding and perforation may increase. In addition, since the plasma half-life of this drug increases and plasma clearance decreases in the elderly, special caution should be exercised when administering this drug to the elderly, and only the minimum effective dose should be administered or the interval between administrations should be increased.
10. Treatment in case of overdose
When administering 360 mg of ketorolac injection per day for 5 days, abdominal pain, peptic ulcer, nausea and vomiting, and erosive gastritis occurred, but recovered after discontinuation of the medication. Metabolic acidosis has been reported after intentional overdose. Ketorolac is not removed by dialysis. Patients are treated according to symptomatic treatment and supportive therapy in case of overdose of general non-steroidal anti-inflammatory analgesics.
11. Application precautions
1) When mixing injection with morphine sulfate, eperidine hydrochloride, promethazine hydrochloride, or hydrolyzine hydrochloride in a small container (syringe, etc.), precipitation may occur, so do not mix in this way.
2) Because this drug contains alcohol, it should not be administered to the central nervous system (epidural or intrathecal).
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Sealed container, protected from light, stored at room temperature (1~30℃)
6. Packaging unit
1mL x 50Amp
7. Expiration date
24 months from date of manufacture
- Active ingredient: Ketorolactromethamine (USP)----30mg
- Additives: Sodium hydroxide, ethanol, sodium chloride, water for injection
2. Effectiveness
1. Short-term therapy for moderate and severe acute pain (including postoperative pain)
2. Children over 2 years of age
Severe postoperative pain for which narcotic analgesics are contraindicated
3. Dosage and dosage
○ Adults: As a ketorolactromethamine salt, 10 mg is administered as an initial dose when administered intramuscularly or intravenously, and a maintenance dose of 10 to 30 mg is administered every 4 to 6 hours. Administer the lowest effective dose. The administration period does not exceed 2 days.
The daily dose should not exceed 90 mg (60 mg for the elderly, patients with renal impairment, and patients weighing less than 50 kg).
Epidural and spinal administration is not performed. The dosage or administration interval can be adjusted depending on the severity of symptoms and pain. Morphine can be administered concurrently if necessary.
○ Children over 2 years of age: Administer as a single intravenous injection after pediatric surgery. Afterwards, it can be administered as an intravenous bolus several times as needed. Since intramuscular injection is painful, intravenous injection is recommended for children. After a single dose of 0.5 to 1.0 mg per kg of body weight, administer 0.5 mg per kg of body weight every 6 hours if necessary. The administration period should not exceed 2 days.
The dosage or administration interval can be adjusted depending on the severity of symptoms and pain.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) The most serious adverse reactions include the following, and caution must be exercised as they may lead to fatal results.
(1) Cardiovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. This risk may increase depending on the duration of administration. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Clinical trials and epidemiological data suggest that the use of COX-2 inhibitors and some NSAIDs, especially at high doses, may slightly increase the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Although ketorolac has not been shown to increase thrombotic adverse events, such as myocardial infarction, there are insufficient data to rule out this risk. This drug should be administered with careful consideration to patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease. Additionally, similar precautions should be taken before starting treatment with this drug in patients with risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, smoking).
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
(2) Hematological risk: Caution should be exercised when administering to patients with coagulation disorders, and patients should be carefully monitored. Although significant interactions between this drug and warfarin or heparin have not been identified in several studies, the risk of bleeding may be increased during concurrent administration of this drug with drugs that affect hemostasis (therapeutic doses of warfarin, heparin, and dextran). In post-marketing studies, signs of postoperative hematoma and wound bleeding have been reported in patients who received intravenous administration of this drug during surgery. The specialist should be aware of the risk of bleeding during surgeries where hemostasis is important, such as (but not limited to) prostatectomy, tonsillectomy, or plastic surgery.
(3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Elderly and debilitated patients may be at greater risk for serious gastrointestinal adverse events.
The possibility of serious gastrointestinal side effects may increase as the administration period and dosage increase, but this risk cannot be completely excluded during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
(4) Kidney: Adverse reactions to the kidneys, ranging from interstitial nephritis to acute renal failure, may occur, and patients with renal disease should be especially careful. When injected, the daily dose should not exceed 60 mg.
(5) Hypersensitivity reaction: Hypersensitivity symptoms such as anaphylaxis, bronchospasm, vascular collapse, hives, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), and vesicular rash may occur. Particular caution should be exercised in patients who have shown hypersensitivity to aspirin or other non-steroidal anti-inflammatory drugs, but the above symptoms may also occur in patients who have not shown hypersensitivity to these drugs or in patients who have not been exposed to these drugs.
(6) Pregnancy: Like other drugs known to inhibit cyclooxygenase/prostaglandin synthesis, this drug may impair fertility and is therefore not recommended for women wishing to become pregnant. Women who are having difficulty conceiving or are undergoing infertility testing should consider discontinuing treatment with this drug.
3) Do not use in combination with other non-steroidal anti-inflammatory drugs (including selective COX-2 inhibitors) as the risk of adverse reactions may increase.
4) Ampoule injections may contain glass fragments when cutting the container, which may cause adverse reactions. When using, cut carefully to minimize glass fragments, but be especially careful when using them on children and the elderly.
2. Do not administer to the following patients (cases).
1) Patients with a history of peptic ulcer or gastrointestinal ulcer/perforation
2) Patients with gastrointestinal bleeding or its history
3) Patients with a predisposition or history of bleeding
4) Patients with or suspected to have cerebrovascular hemorrhage or patients with a history of cerebrovascular hemorrhage
5) Patients who have undergone surgery and have a high risk of bleeding or incomplete hemostasis
6) Patients with moderate or severe renal failure (serum creatinine >160 μmo/L) or patients at risk of renal failure due to volume loss or dehydration
7) Patients with bronchial asthma or a history of it
8) Patients with nasal polyps, angioedema, or bronchospasm symptoms
9) Patients with hypersensitivity to this drug, its components, aspirin, or non-steroidal anti-inflammatory drugs
10) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactic reactions after administration of non-steroidal anti-inflammatory drugs have been rarely reported.)
11) Patients who underwent tonsillectomy surgery
12) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
13) Patients receiving other non-steroidal anti-inflammatory drugs
14) Patients receiving anticoagulants, pentoxifylline, probenecid, and lithium
15) Pregnant women, women who may be pregnant, or lactating women
16) Patients with severe heart failure
17) Patients with severe liver impairment
18) Patients with hypovolemia due to dehydration or other causes
19) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
20) Infants under 2 years of age
3. Administer with caution to the following patients.
1) Patients with hepatic impairment or its history
2) Patients with renal impairment or its history
3) Elderly people
4) Patients with high blood pressure
5) Patients with fluid retention or heart failure
6) Patients with hypovolemia, dehydration, and patients taking diuretics or ACE inhibitors
7) Patients with a history of gastrointestinal diseases such as Crohn's disease or ulcerative colitis (symptoms may worsen)
8) Patients with bronchial asthma
9) Patients who have had digestive ulcers due to long-term administration of non-steroidal anti-inflammatory drugs in the past, and who require long-term administration of this drug and are concurrently being treated with peptic ulcers such as misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
4. Adverse reactions
1) Digestive system: Nausea, indigestion, gastrointestinal pain, diarrhea, sometimes constipation, abdominal distension, vomiting, stomatitis, rarely peptic ulcer, gastrointestinal bleeding, perforation, bloody stool, rectal bleeding, gastritis, burping, anorexia, increased appetite, pancreatitis, hematemesis, esophagitis, melena, dry mouth, colitis, and exacerbation of Crohn's disease.
2) Whole body: Occasionally, edema, rarely anaphylaxis, bronchospasm, laryngeal edema, tongue edema, hypotension, flushing, hypersensitivity reactions such as rash, weight gain, fever, infection, and asthenia may occur.
3) Cardiovascular system: High blood pressure, rarely flushing, palpitations, pallor, low blood pressure, syncope, bradycardia, chest pain, and heart failure may occur.
4) Skin: Redness, sometimes itching, rarely toxic epidermal necrolysis (Riel syndrome), drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome), mucocutaneous ocular syndrome (Stevens-Johnson syndrome), exfoliative dermatitis, papular redness, urticaria, angioedema, and sweating may occur.
5) Blood and lymphatic system: Purpura, rarely surgical site bleeding, thrombocytopenia, nosebleeds, anemia, leukopenia, eosinophilia, and hematoma may occur.
6) Nervous system: Headache, sweating, occasional drowsiness, dizziness, rarely convulsions, tremors, hallucinations, abnormal dreams, strange situation hallucinations, extrapyramidal syndrome, paresthesia, depression, insomnia, nervousness, dry mouth, severe thirst, abnormal thinking, difficulty concentrating, hyperkinesia, stupor, muscle pain, aseptic meningitis (especially those suffering from autoimmune diseases such as systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD) patient), anxiety, and psychotic reactions may occur.
7) Liver: In rare cases, hepatitis, liver failure, cholestatic jaundice, and abnormal liver function test values may occur. If these symptoms appear, administration should be discontinued immediately.
8) Respiratory system: In rare cases, shortness of breath, asthma, pulmonary edema, rhinitis, and cough may occur.
9) Urinary system: In rare cases, acute renal failure, flank pain (sometimes accompanied by hematuria and azotemia), oliguria, nephritis, polyuria, frequent urination, urinary retention, hemolytic uremia, hyperkalemia, hyponatremia, nephrotic syndrome, and increased serum urea and creatinine levels may occur.
10) Others: Occasionally, pain at the injection site, abnormal taste, visual abnormality, blurred vision, optic neuritis, tinnitus, hearing loss, infertility in women, and prolonged bleeding time may occur.
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient. In particular, the lowest effective dose should be used in patients weighing less than 50 kg, over 65 years of age, or with renal dysfunction, and do not exceed 60 mg per day when injected.
2) Gastrointestinal adverse reactions: In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding occurs more than 10 times when administered non-steroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding or ulcers include oral corticosteroids, anticoagulants such as warfarin, concomitant use of antiplatelet drugs such as selective serotonin reuptake inhibitors or aspirin, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Caution should be exercised when administering nonsteroidal anti-inflammatory drugs to patients with a history of inflammatory bowel disease (ulcerative enteritis, Crohn's disease) because the disease may worsen. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients. If gastrointestinal bleeding or ulceration occurs in a patient receiving this drug, administration should be discontinued.
3) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention, hypertension, and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention, heart failure, hypertension, or similar diseases.
5) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, hypovolemia, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory drugs, including this drug, may increase liver function values (AST, ALT). These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the administration period, and if clinical symptoms or systemic signs related to liver disease (e.g., eosinophilia, rash) appear, administration should be immediately discontinued.
8) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. Patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants, should be carefully monitored when receiving this drug.
9) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should have a complete blood count (CBC) and physicochemical tests performed regularly. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
10) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who develop severe, potentially fatal bronchospasm with or without nasal polyps after taking aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
11) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
12) Drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome): Drug reaction with increased eosinophils and systemic symptoms (DRESS syndrome) has been reported in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). Some of these cases were fatal or life-threatening. DRESS syndrome is usually, but not always, accompanied by fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, and myositis. Sometimes the symptoms of DRESS syndrome may resemble an acute viral infection. Eosinophilia is often present.
Because this disorder is variable in its presentation, other organ systems not mentioned here may be involved. It is important to note that early symptoms of hypersensitivity, such as fever or lymphadenopathy, may appear even if the rash is not evident. If these signs or symptoms occur, this drug should be discontinued immediately and the patient evaluated.
13) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients.
14) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
15) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
16) This drug has no sedative or anti-anxiety effect and has an inhibitory effect on platelet aggregation, which delays hemostasis time and increases the risk of bleeding. Therefore, it should not be used as an anesthetic aid before surgery or during surgery.
17) This drug has not been sufficiently studied as an analgesic in the obstetric field, and it is not used in this field because it is a prostaglandin biosynthesis inhibitor and affects uterine contractions and fetal circulation.
18) Use of this drug may cause depression, insomnia, dizziness, and drowsiness. Therefore, you must be careful when driving or operating machinery.
19) Temporary infertility has been reported in women taking NSAIDs for a long time.
20) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
6. Interaction
1) ACE inhibitor or angiotensin II receptor antagonist
(1) Concurrent use with ACE inhibitors may increase the risk of kidney damage (especially in patients with volume depletion).
(2) There are reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory drugs, so this interaction should be kept in mind when coadministering this drug with ACE inhibitors or angiotensin II receptor antagonists.
2) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
3) At the therapeutic concentration of salicylic acid (300 g/mL), the plasma protein content of this drug drops from 99.2% to 97.5%.
4) Diuretics (furosemide, etc.): Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
5) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
6) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered concurrently with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
7) Anticoagulants (heparin, warfarin, or coumarin)
(1) When heparin or coumarin derivatives are used together at therapeutic doses, the risk of complications due to bleeding may increase. There are no sufficient research results on the combined use of low-dose heparin (2,500-5,000 U, q12h), warfarin, and dextran, but the risk of bleeding is expected to increase.
(2) For gastrointestinal bleeding, warfarin and non-steroidal anti-inflammatory drugs may have a synergistic effect, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
(3) This drug slightly reduces the plasma protein binding rate of warfarin, but does not affect the plasma protein binding rate of this drug at the therapeutic concentration of warfarin.
8) It has been shown to reduce the requirement for opiate analgesics when administered to relieve postoperative pain.
9) The therapeutic concentrations of digoxin, ibuprofen, naproxen, acetaminophen, phenytoin, tolbutamide, and piroxicam do not affect the plasma protein rate of this drug.
10) Antihypertensive agent: Reduces antihypertensive effect.
11) Cyclosporine and tacrolimus: Nephrotoxicity may increase with concurrent administration with non-steroidal anti-inflammatory drugs.
12) Mifepristone: Non-steroidal anti-inflammatory drugs should not be administered for 8 to 12 days after taking mifepristone because they reduce the effectiveness of mifepristone.
13) Oxpentiphylline: Concomitant use should be avoided because bleeding tendency increases when administered together.
14) Quinolone antibiotics: Be careful because there is animal testing data that shows that the risk of convulsions may increase when administered in combination with non-steroidal anti-inflammatory analgesics.
15) Zidovudine: Hematological toxicity may increase when administered in combination with non-steroidal anti-inflammatory drugs. There is evidence that coadministration of zidovudine and ibuprofen in patients with HIV(+) hemophilia increases the risk of hemarthrosis and hematoma.
16) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
17) Cardiac glycosides: Non-steroidal anti-inflammatory drugs can worsen heart failure by decreasing the glomerular filtration rate and increasing the blood concentration of glycosides.
18) Corticosteroid preparations: Be careful as the risk of gastrointestinal ulcers or bleeding may increase.
7. Administration to pregnant and lactating women
1) Safety for pregnant women has not been established, so do not administer to pregnant women or women who may be pregnant.
2) Like other non-steroidal anti-inflammatory drugs, this drug may cause premature closure of the fetus's ductus arteriosus when administered at the end of pregnancy.
3) In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased fetal survival rate.
4) It has been reported that this drug and its metabolites pass into the breast milk of fetuses and animals. Because this drug has been detected in low concentrations in human breast milk, it is not administered to nursing mothers.
8. Administration to children
Safety and efficacy in infants under 2 years of age have not been established, so do not administer to infants under 2 years of age.
9. Administration to elderly people
Elderly people are more sensitive to adverse reactions to the kidneys from non-steroidal anti-inflammatory drugs, and the incidence of adverse reactions such as gastrointestinal bleeding and perforation may increase. In addition, since the plasma half-life of this drug increases and plasma clearance decreases in the elderly, special caution should be exercised when administering this drug to the elderly, and only the minimum effective dose should be administered or the interval between administrations should be increased.
10. Treatment in case of overdose
When administering 360 mg of ketorolac injection per day for 5 days, abdominal pain, peptic ulcer, nausea and vomiting, and erosive gastritis occurred, but recovered after discontinuation of the medication. Metabolic acidosis has been reported after intentional overdose. Ketorolac is not removed by dialysis. Patients are treated according to symptomatic treatment and supportive therapy in case of overdose of general non-steroidal anti-inflammatory analgesics.
11. Application precautions
1) When mixing injection with morphine sulfate, eperidine hydrochloride, promethazine hydrochloride, or hydrolyzine hydrochloride in a small container (syringe, etc.), precipitation may occur, so do not mix in this way.
2) Because this drug contains alcohol, it should not be administered to the central nervous system (epidural or intrathecal).
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Sealed container, protected from light, stored at room temperature (1~30℃)
6. Packaging unit
1mL x 50Amp
7. Expiration date
24 months from date of manufacture
Product Updates
Total 3items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 3 | Ketolan Inj. | Precautions for use | 2024.05.22 | PDFKetoran Injection_Precautions for use.pdf |
| 2 | Ketolan Inj. | Ketoran Injection (effectiveness, dosage, precautions for use... | 2011.12.29 | HWPKetoran Injection Effectiveness_UsageDosage_Precautions for Use.hwp |
| 1 | Ketolan Inj. | Ketoranju (Precautions for use) | 2008.04.21 | HWPChange in Ketoran Injection (Precautions for Use) (2008.04.30).hwp |